Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.
Fabbri A, Nelli F, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Scagnoli S, Pisegna S, Alesini D, Sini V, Orlandi A, Fabi A, Piacentini F, Moscetti L, D'Auria G, Gamucci T, Mazzotta M, Pizzuti L, Vici P, Cretella E, Scavina P, La Cesa A, Persano M, Atzori F, Ruggeri EM. Fabbri A, et al. Among authors: marrucci e. Front Oncol. 2023 Jun 27;13:1177681. doi: 10.3389/fonc.2023.1177681. eCollection 2023. Front Oncol. 2023. PMID: 37441419 Free PMC article.
Colon metastasis from recurrent gallbladder cancer: a case report.
Signorelli C, Marrucci E, Cristi E, Pastorelli A, Cardello P, Chilelli MG, Zampaletta C, Ruggeri EM. Signorelli C, et al. Among authors: marrucci e. AME Case Rep. 2021 Jul 25;5:21. doi: 10.21037/acr-20-167. eCollection 2021. AME Case Rep. 2021. PMID: 34312600 Free PMC article.
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study.
Nelli F, Fabbri A, Onorato A, Giannarelli D, Silvestri MA, Giron Berrios JR, Virtuoso A, Marrucci E, Signorelli C, Chilelli MG, Primi F, Schirripa M, Mazzotta M, Ruggeri EM. Nelli F, et al. Among authors: marrucci e. Ann Oncol. 2022 Jan;33(1):107-108. doi: 10.1016/j.annonc.2021.09.009. Epub 2021 Sep 20. Ann Oncol. 2022. PMID: 34555502 Free PMC article. No abstract available.
Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study.
Nelli F, Fabbri A, Onorato A, Giannarelli D, Silvestri MA, Pessina G, Giron Berrios JR, Virtuoso A, Marrucci E, Schirripa M, Mazzotta M, Panichi V, Cercola P, Signorelli C, Chilelli MG, Primi F, Ruggeri EM. Nelli F, et al. Among authors: marrucci e. Ann Oncol. 2022 Mar;33(3):352-354. doi: 10.1016/j.annonc.2021.12.001. Epub 2021 Dec 10. Ann Oncol. 2022. PMID: 34896598 Free PMC article. No abstract available.
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study.
Ruggeri EM, Nelli F, Fabbri A, Onorato A, Giannarelli D, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Panichi V, Pessina G, Signorelli C, Chilelli MG, Primi F, Natoni F, Fazio S, Silvestri MA. Ruggeri EM, et al. Among authors: marrucci e. ESMO Open. 2022 Feb;7(1):100350. doi: 10.1016/j.esmoop.2021.100350. Epub 2021 Nov 27. ESMO Open. 2022. PMID: 34942438 Free PMC article.
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature.
Botticelli A, Fabbri A, Roberto M, Alesini D, Cirillo A, D'Auria G, Krasniqi E, Marrucci E, Muratore M, Pantano F, Pizzuti L, Portarena I, Rossi R, Scagnoli S, Marchetti P. Botticelli A, et al. Among authors: marrucci e. Front Oncol. 2022 Feb 9;12:797157. doi: 10.3389/fonc.2022.797157. eCollection 2022. Front Oncol. 2022. PMID: 35223478 Free PMC article.
Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study.
Nelli F, Virtuoso A, Berrios JRG, Giannarelli D, Fabbri A, Marrucci E, Ruggeri EM. Nelli F, et al. Among authors: marrucci e. Cancer Chemother Pharmacol. 2022 Apr;89(4):529-537. doi: 10.1007/s00280-022-04416-4. Epub 2022 Mar 18. Cancer Chemother Pharmacol. 2022. PMID: 35301584
Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival.
Chilelli MG, Signorelli C, Giron Berrios JR, Onorato A, Nelli F, Fabbri MA, Primi F, Marrucci E, Virtuoso A, Schirripa M, Mazzotta M, Ruggeri EM. Chilelli MG, et al. Among authors: marrucci e. Cancer Diagn Progn. 2022 Jan 3;2(1):55-63. doi: 10.21873/cdp.10076. eCollection 2022 Jan-Feb. Cancer Diagn Progn. 2022. PMID: 35400002 Free PMC article.
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study.
Nelli F, Giannarelli D, Fabbri A, Silvestri MA, Berrios JRG, Virtuoso A, Marrucci E, Schirripa M, Mazzotta M, Onorato A, Panichi V, Topini G, Pessina G, Natoni F, Signorelli C, Chilelli MG, Primi F, Ruggeri EM. Nelli F, et al. Among authors: marrucci e. Ann Oncol. 2022 Jul;33(7):740-742. doi: 10.1016/j.annonc.2022.04.002. Epub 2022 Apr 9. Ann Oncol. 2022. PMID: 35413398 Free PMC article. No abstract available.
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study.
Nelli F, Fabbri A, Panichi V, Giannarelli D, Topini G, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Signorelli C, Chilelli MG, Primi F, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: marrucci e. Int Immunopharmacol. 2022 Jul;108:108774. doi: 10.1016/j.intimp.2022.108774. Epub 2022 Apr 14. Int Immunopharmacol. 2022. PMID: 35461110 Free PMC article.
32 results